May 28, 2020
InvaGen Pharmaceuticals Inc. is recalling 2200 bottles of gabapentin tablets after samples failed to meet impurity specifications during routine testing, according to the May 27, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 600-mg gabapentin tablets in 500-count bottles (NDC 76282-405-05) manufactured by InvaGen Pharmaceuticals for Exelan Pharmaceuticals. The recalled tablets are from lot NB900413 (Exp. 12/20) and were distributed throughout the United States.
InvaGen Pharmaceuticals initiated the voluntary recall May 14, 2020. On May 21, 2020, the FDA designated the recall Class III. Under the recall classification, use of the affected tablets is not likely to cause harm.
Gabapentin is a prescription anticonvulsant used to treat seizures and neuropathic pain caused by shingles.